Therefore, multiple PI3K inhibitors and MEK inhibitors have been employed and showed significant effect on increasing of trastuzumab sensitivity or reversing trastuzumab resistance of HER2+ BC patients [10–13]. Here, ERBB2 is linked to breast cancer.